经会阴前列腺靶向穿刺和系统穿刺与根治术后病理结果的一致性分析

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (279 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的: 探讨经直肠超声多参数磁共振（TRUSmpMRI）图像融合引导下经会阴前列腺靶向穿刺活检与根治性前列腺切除术后病理结果的一致性。方法: 回顾性分析2017年1月至2019年6月行TRUSmpMRI图像融合经会阴前列腺穿刺活检确诊为前列腺癌患者383例的临床资料。所有患者穿刺前已完善mpMRI，并对mpMRI上出现的可疑病灶经确认后行前列腺图像报告和数据系统（PIRADS）评分。每例患者均在局麻下行TRUSmpMRI图像融合引导下的经会阴前列腺靶向穿刺,之后进行标准12针系统穿刺。比较并分析靶向穿刺、系统穿刺结果与根治性前列腺切除术后病理结果的一致性。结果：靶向穿刺中有68例(17.75%)患者出现病理结果升级，显著低于系统穿刺中104例（27.15%）出现病理结果升级（P=0.002）；靶向穿刺中有63例（16.45%）患者出现病理结果降级，系统穿刺中有71例（18.54%）患者出现病理结果降级，两种穿刺方法在病理降级上无统计学差异。结论： TRUSmpMRI图像融合经会阴前列腺靶向穿刺活检相比系统穿刺活检的病理结果更接近根治性前列腺切除术后病理结果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	庄君龙
	尹皓立
	阚延晟
	汪维
	郭宏骞

关键词 ：经直肠超声, 磁共振, 靶向穿刺, 病理升级, 前列腺癌

收稿日期: 2020-03-23

基金资助:江苏省卫计委青年基金资助项目（Q2017005）

通讯作者: 郭宏骞（通讯作者），主任医师，博士生导师，E-mail: dr.ghq@nju.edu.cn

作者简介: 庄君龙（1988—），男，博士，主治医师

引用本文:

庄君龙，尹皓立，阚延晟，汪维，郭宏骞. 经会阴前列腺靶向穿刺和系统穿刺与根治术后病理结果的一致性分析[J]. 江苏大学学报:医学版, 2020, 30(04): 361-363.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2020/V30/I04/361

［1］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020\[J\]. CA Cancer J Clin, 2020, 70(1):7-30.

［2］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015\[J\]. CA Cancer J Clin, 2016, 66(2):115-132.

［3］Presti JC Jr, O′ Dowd GJ, Miller MC, et al. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multipractice study\[J\]. J Urol, 2003, 169(1): 125-129.

［4］CamposFernandes JL, Bastien L, Nicolaiew N, et al. Prostate cancer detection rate in patients with repeated extended 21sample needle biopsy\[J\]. Eur Urol, 2009, 55(3): 600-606.

［5］Haffner J, Lemaitre L, Puech P, et al.Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imagingtargeted and systematic biopsy for significant prostate cancer detection\[J\]. BJU Int, 2011,108(8 Pt 2): E171-E178.

［6］Liu W, Patil D, Howard DH, et al. Adoption of prebiopsy magnetic resonance imaging for men undergoing prostate biopsy in the United States\[J\]. Urology, 2018,117:57-63.

［7］Rosenkrantz AB, Hemingway J, Hughes DR, et al. Evolving use of prebiopsy prostate magnetic resonance imaging in the medicare population\[J\]. J Urol, 2018, 200(1):89-94.

［8］王友林, 朱磊一, 姜波,等. 超声引导下经直肠前列腺穿刺与前列腺癌根治术后病理组织Gleason评分差异性的研究\[J\]. 临床泌尿外科杂志, 2015, 30(7):628-630.

［9］汪维, 张青, 张冰,等. 多指数磁共振与经直肠超声图像融合靶向引导经会阴前列腺穿刺活检的初步研究\[J\]. 中华超声影像学杂志, 2015,24(9):793-796.

［10］Iu PP. ESUR prostate MR guidelines\[J\]. Eur Radiol, 2013, 23(8):2320-2321.

［11］Lo GC, Margolis DJA. Prostate MRI with PIRADS v2.1: initial detection and active surveillance\[J\]. Abdom Radiol (NY), 2020,45(7):2133-2142.

［12］Singh AK, Kruecker J, Xu S, et al. Initial clinical experience with real time transrectal ultrasonographymagnetic resonance imaging fusionguided prostate biopsy\[J\]. BJU Int, 2008, 101(7):841-845.

［13］Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system\[J\]. Am J Surg Pathol, 2016, 40(2):244-252.

［14］Rouvière O, Puech P, RenardPenna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsynaive patients (MRIFIRST): A prospective, multicentre, paired diagnostic study\[J\]. Lancet Oncol, 2019, 20(1):100-109.

［15］Goel S, Shoag JE, Gross MD, et al. Concordance between biopsy and radical prostatectomy pathology in the

era of targeted biopsy: A systematic review and metaanalysis\[J\]. Eur Urol Oncol, 2020, 3(1):10-20.

［16］Alchin DR, Murphy D, Lawrentschuk N. Risk factors for Gleason score upgrading following radical prostatectomy\[J\]. Minerva Urol Nefrol, 2017, 69(5):459-465.

［17］Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intentupdate 2013\[J\]. Eur Urol, 2014, 65(1):124-137.

［18］Siddiqui MM, RaisBahrami S, Truong H, et al. Magnetic resonance imaging/ultrasoundfusion biopsy significantly upgrades prostate cancer versus systematic 12core transrectal ultrasound biopsy\[J\]. Eur Urol, 2013, 64(5):713-719.

［19］Ingham M, Mossanen M, Wang Y, et al. Costeffectiveness analysis of magnetic resonance imagingultrasound fusion biopsy versus systematic transrectal ultrasoundguided biopsy in diagnosing prostate cancer\[J\]. J Clin Oncol, 2017, 35(6 suppl)：25.

［20］Radtke JP, Schwab C, Wolf MB, et al. Multiparametric magnetic resonance imaging (MRI) and MRItransrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen\[J\]. Eur Urol, 2016, 70(5):846-853.

［21］Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer\[J\]. BJU Int, 2002, 89(6):538-542.

［22］Gansler T, Fedewa S, Qi R, et al. Most Gleason 8 biopsies are downgraded at prostatectomy—does 4+4=7?\[J\]. J Urol, 2018, 199(3):706-712.